热门资讯> 正文
Surmodics合并交易引发FTC第二次请求
2024-08-13 19:00
- Medical device maker Surmodics (NASDAQ:SRDX) announced Tuesday that the Federal Trade Commission (FTC) has requested more information on its pending merger agreement with the affiliates of private equity firm GTCR.
- Surmodics (SRDX) and BCE Parent, LLC, an affiliate of a GTCR-backed entity, received the FTC Second Request on Aug. 12, the company said in a regulatory filing.
- It is meant to extend the waiting period imposed by the antitrust regulation, the Hart-Scott-Rodino Antitrust Improvements Act of 1976, until 30 days after the merging entities comply with the request.
- Surmodics (SRDX) added that the deal is expected to conclude before Feb. 28, 2025, the outside date mentioned in the merger agreement.
- When the company and acquirer signed the all-cash buyout deal in March, they expected to conclude the transaction in H2, 2024.
More on Surmodics
- Surmodics beats top-line and bottom-line estimates; suspends annual guidance
- Surmodics jumps 18% on acquisition by GTCR
- Seeking Alpha’s Quant Rating on Surmodics
- Historical earnings data for Surmodics
- Financial information for Surmodics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
